Herzing NU670 2021 April Unit 7 Assignment Clinical Practice Portfolio Latest
NU670 Advanced Psychopharmacology and Health Promotion
Unit 7 Assignment
PSYCHIATRIC MENTAL HEALTH NURSE PRACTITIONER CLINICAL PRACTICE PORTFOLIO
Table of Contents
NU670 Psychopharmacology and Health promotion
Neurotransmitter Chart (Unit 1)
Antipsychotics Chart (Unit 2)
Antidepressants, Anxiolytics, & Mood Stabilizers Chart (Unit 3, 4, 5)
Substance Use Resources (Chart links) (Unit 6)
Additional Resources List
|
Neurotransmitters Chart |
|||||||||||||||||||
|
|
Function (Excitatory or Inhibitory) |
Locations |
Receptors |
Effects of Deficient |
Effects of Surplus |
Agonist Drug |
Antagonist Drug |
||||||||||||
|
Acetylcholine |
|
|
|
|
|
|
|
||||||||||||
|
Dopamine |
|
|
|
|
|
|
|
||||||||||||
|
Endorphins |
|
|
|
|
|
|
|
||||||||||||
|
GABA |
|
|
|
|
|
|
|
||||||||||||
|
Glutamate |
|
|
|
|
|
|
|
||||||||||||
|
Glycine |
|
|
|
|
|
|
|
||||||||||||
|
Glutamate |
|
|
|
|
|
|
|
||||||||||||
|
Norepinephrine |
|
|
|
|
|
|
|
||||||||||||
|
Serotonin |
|
|
|
|
|
|
|
||||||||||||
|
Antipsychotics |
|||||||||||||||||||
|
First Generation |
|
|
|
|
|
|
|
Side Effects (L=Low, M=Moderate, H=High) |
|
||||||||||
|
Generic Name |
Trade Name |
Route(s) of Administration |
LAI option |
Starting Dose |
Half Life |
Indications (s/sx& diagnosis) |
MOA (neurotransmitter effects) |
EPS |
Hyperlipidemia |
T2DM |
Weight Gain |
Cognitive Issue |
Other SE |
Costs |
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Second Generation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Antidepressants, Anxiolytics & Mood Stabilizers |
||||||||||||||
|
Antidepressants |
|
|
|
|
|
|
|
Side Effects (L=Low, M=Moderate, H=High) |
|
|||||
|
Generic Name |
Trade Name |
Route(s) of Administration |
LAI option |
Starting Dose |
Half Life |
Indications (s/sx& diagnosis) |
MOA (neurotransmitter effects) |
EPS |
Hyperlipidemia |
T2DM |
Weight Gain |
Cognitive Issue |
Other SE |
Costs |
|
SSRIs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SNRIs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TCAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MAOIs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Atypical |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anxiolytics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benzodiazepines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Barbiturates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mood Stabilizers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
Substance Use Resources
Commonly Used Drugs and Treatment Information Charts:
https://www.drugabuse.gov/sites/default/files/Commonly-Used-Drugs-Charts_final_June_2020_optimized.pdf
https://www.drugabuse.gov/sites/default/files/nida_commonlyuseddrugs_final_printready.pdf
Withdrawal Sx Chart
https://www.drugabuse.gov/sites/default/files/nida_commonlyabused_withdrawalsymptoms_10062017-508-1.pdf
-
Rating:
/5
Solution: Herzing NU670 2021 April Unit 7 Assignment Clinical Practice Portfolio Latest